首頁 > 市場調查報告書 > 製藥

疫苗癌症

市場調查報告書

商品編碼

1684190

個人化癌症疫苗全球市場：市場機會與臨床試驗展望（2025年）

Global Personalized Cancer Vaccine Market Opportunity & Clinical Trials Outlook 2025

出版日期: 2025年03月01日 | 出版商:

KuicK Research | 英文 130 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

在生物技術進步和標靶治療需求不斷成長的推動下，個人化癌症疫苗成為下一代癌症治療的變革力量，並具有新興的商業潛力。這些疫苗是針對癌症的客製化治療方法，利用患者獨特的基因組成來製造專門針對和消滅癌細胞的疫苗。這種方法的成功獲得關注，個人化癌症疫苗市場預計到2030年將大幅成長。 BioNTech、Moderna 和 myNEO Therapeutics 等規模較小的公司都站在前線，利用在 COVID-19 大流行期間磨練的mRNA 技術專業知識。

個人化癌症疫苗的興起很大程度上歸功於精準醫療革命，它根據每個患者的特徵量身定制治療方案。這些疫苗比傳統治療有幾個優勢，包括更高的特異性和有效性。例如，BioNTech 因其在個人化 mRNA 癌症疫苗方面的工作而備受關注，尤其是透過與製藥巨頭 Genentech 合作治療胰臟癌。此次合作促成了基於 BioNTech 的iNeST 技術平台的自體基因cevumeran的開發。自體基因cevumeran目前進行一項針對胰臟導管腺癌、黑色素瘤和大腸直腸癌的臨床試驗。此次合作證明了將先進的mRNA 技術與個人化醫療相結合以治療以前難以治療的癌症的潛力。

個人化癌症疫苗的投資也蓬勃發展，創投家和製藥公司向新創公司和合作公司投入了數十億美元。例如，Merck公司和 Moderna 公司的合作已經取得了令人欣喜的成果，為癌症疫苗的未來帶來了樂觀的前景。然而儘管這項技術令人興奮，但挑戰依然存在。由於個人化癌症疫苗是針對每個人量身定制的，因此每位患者的生產成本可能超過 100,000 美元。高昂的成本是近期限制此類疫苗廣泛使用的主要障礙之一。

好消息是，人工智慧輔助新抗原選擇和機器人疫苗合成等自動化技術的持續進步有望長期降低製造成本。這些創新有望幫助簡化疫苗開發並使更多患者能夠獲得治療。此外，隨著規模經濟的實現，生產成本預計將下降，使個人化癌症疫苗在長期內更具成本效益。

儘管存在上述挑戰，個人化癌症疫苗有望在未來幾年成為癌症治療組合的基石。伴隨診斷的日益普及將改善患者的選擇，並確保那些最有可能從這些疫苗中受益的人接種疫苗。這有可能重新定義癌症的治療方式，從一刀切的治療模式轉變為個人化、精準和更有效的治療模式。

總之，圍繞個人化癌症疫苗的商業生態系統迅速發展，具有巨大的創新和獲利機會。疫苗有望徹底改變癌症治療，但解決製造業、智慧財產權、償付等複雜問題將是充分發揮其潛力的關鍵。隨著技術的不斷進步和領域的不斷成熟，個人化癌症疫苗可能成為一種標準治療選擇，為世界各地的患者帶來希望，並有可能重塑癌症治療的未來。

本報告研究了全球個人化癌症疫苗市場，並概述了市場以及藥物趨勢、臨床試驗趨勢、區域趨勢以及進入市場的公司的競爭格局。

Commercially Approved Personalized Cancer Vaccine: Provenge
Provenge Patent , Price & Dosage Insight
Global Clinical Research Trends By Region & Indication
Insight On More Than 18 Personalized Cancer Vaccines In Clinical Trials
Personalized Cancer Vaccines Clinical Insight By Developer, Indication & Phase
Insight On Key Personalized Cancer Vaccines Proprietary Development Platforms
Competitive Landscape

Personalized cancer vaccines are emerging as a transformative force in next generation cancer treatment methodology, with emergent commercial potential fueled by advancements in biotechnology and an increasing demand for targeted therapies. These vaccines represent a tailored approach to cancer treatment, utilizing a patient's unique genetic makeup to craft vaccines that specifically target and eliminate cancer cells. The success of this approach is gaining traction, and the market for personalized cancer vaccines is expected to grow significantly by 2030. Companies like BioNTech, Moderna, and smaller players such as myNEO Therapeutics are at the forefront, using their expertise in mRNA technology, which was initially honed during the COVID-19 pandemic.

The rise of personalized cancer vaccines is largely driven by the precision medicine revolution, which tailors treatments to individual patient characteristics. These vaccines offer several advantages over traditional therapies, including greater specificity and efficacy. BioNTech, for example, has gained attention for its work on personalized mRNA cancer vaccines, particularly through its collaboration with pharmaceutical giant Genentech to target pancreatic cancer. This partnership has led to the development of autogene cevumeran, which is based on BioNTech's iNeST technology platform. Autogene cevumeran is currently being tested in clinical trials for pancreatic ductal adenocarcinoma, melanoma, and colorectal cancer. The collaboration demonstrates the potential of combining advanced mRNA technology with personalized treatments to address cancers that have historically been difficult to treat.

Investment in personalized cancer vaccines is also soaring, with venture capital firms and pharmaceutical companies pouring significant funds into startups and partnerships. The collaboration between Merck and Moderna, for example, has already demonstrated promising results, contributing to the growing optimism around the future of cancer vaccines. However, despite the excitement surrounding the technology, challenges remain-particularly in manufacturing. Since personalized cancer vaccines are bespoke treatments tailored to each individual, production costs can exceed $100,000 per patient. This high cost is one of the major hurdles that could limit the widespread adoption of these vaccines in the near term.

The good news is that ongoing advancements in automation technologies, including AI-driven neoantigen selection and robotic vaccine synthesis, are expected to reduce production costs over time. These innovations will help streamline vaccine development and make the treatment more accessible to a broader patient population. Furthermore, as economies of scale come into play, the cost of production is likely to decrease, helping to make personalized cancer vaccines more cost-effective in the long term.

Despite the aforementioned challenges, personalized cancer vaccines are anticipated to become a cornerstone of oncology treatment portfolios in the coming years. The increasing availability of companion diagnostics will help refine patient selection, ensuring that those most likely to benefit from these vaccines receive them. This could potentially redefine how cancers are treated, shifting from a one-size-fits-all model to one that is personalized, precise, and more effective.

In conclusion, the commercial ecosystem surrounding personalized cancer vaccines is evolving rapidly, with significant opportunities for innovation and profitability. The promise of these vaccines to revolutionize cancer treatment is clear, but successful navigation of the complexities of manufacturing, intellectual property, and reimbursement will be key to realizing their full potential. As technology continues to advance and the field matures, personalized cancer vaccines could become a standard treatment option, offering hope for patients worldwide and reshaping the future of cancer care.

1. Personalized Cancer Vaccines As Next Generation Immunotherapeutic Approach

1.1 Approach To Cancer Vaccine Strategy
1.2 Cancer Vaccines - Current Progress & Challenges

2. Personalized Cancer Vaccine Mechanism Of Action

2.1 Role of Tumor Neoantigens & Human Leukocyte Antigen
2.2 Personalized Cancer Vaccine Working Mechanism
2.3 Genetic Polymorphism In Pharmacogenomics
2.4 Cancer Pharmacogenomics & Somatic Mutations

3. Role of Biomarkers In Personalized Vaccines

3.1 Pharmacogenomic Biomarkers
3.2 Prognostic & Predictive Biomarkers

4. Provenge - 1st Approved Personalized Cancer Vaccine

4.1 Overview & Patent Insight
4.2 Pricing & Dosing Insight

5. Personalized Cancer Vaccines Clinical Insight By Developer, Indication & Phase

6. Current Clinical Development & Future Commercialization Outlook

6.1 Current Market Development Scenario
6.2 Future Market Outlook

7. Personalized Cancer Vaccines Clinical Tends & Developments Insight By Indication

7.1 Melanoma
7.2 Lung Cancer
7.3 Breast Cancer
7.4 Prostate Cancer
7.5 Gastrointestinal Cancers
7.6 Gynecological Cancers
7.7 Brain Tumor
7.8 Hematological Malignancies

8. Personalized Cancer Vaccines Clinical & Market Insight By Region

8.1 US
8.2 EU
8.3 China
8.4 India
8.5 Australia
8.6 South Korea
8.7 Taiwan
8.8 UK

9. Personalized Cancer Vaccines Proprietary Development Platforms

9.1 BioNTech - iNeST
9.2 BioVaxys - DPX & Haptenix Platforms
9.3 CureVac - proprietary mRNA technology
9.4 Evaxion - PIONEER & ObsERV Technologies
9.5 Geneos - GT-EPIC(TM) platform
9.6 Moderna - mRNA Design Studio
9.7 myNEO Therapeutics - ImmunoEngine
9.8 Nouscom - Unnamed Technology
9.9 Nykode Therapeutics - Vaccibody
9.10 Transgene - myvac

10. Personalized Cancer Vaccine Market Dynamics

10.1 Market Drivers & Opportunities
10.2 Market Challenges & Restraints

11. Competitive Landscape

11.1 BioNtech AG
11.2 CureVac AG
11.3 Evaxion Biotech
11.4 Geneos Therapeutics
11.5 Genentech
11.6 Merck
11.7 Moderna Therapeutics
11.8 NeoCura
11.9 Transgene
11.10 TuHURA Biosciences

簡介目錄圖表

List of Figures

Figure 1-1: Cancer Vaccine Types
Figure 1-2: Advantages Of Targeting Neoantigens In Cancer Vaccine Development
Figure 2-1: Personalized Cancer Vaccine - Mechanism
Figure 2-2: Demonstrating Genomic Polymorphism In Pharmacogenomics
Figure 2-3: Source of Pharmacological & Pharmacogenetic Variability
Figure 3-1: Biomarkers In Personalized Medicine
Figure 3-2: Roadmap For Developing Predictive Biomarkers
Figure 4-1: Provenge - Approval Year By Region
Figure 4-2: Provenge - Cost Per Unit & Supply (US$), March'2025
Figure 6-1: Global Personalized Cancer Vaccines Market - Future Outlook
Figure 7-1: KEYNOTE-942 Phase 2 Study (NCT03897881) - Initiation & Completion Year
Figure 7-2: BNT111-01 Phase 2 Study (NCT04526899) - Initiation & Completion Year
Figure 7-3: KEYNOTE-D36 Phase 2 Study (NCT05309421) - Initiation & Completion Year
Figure 7-4: MC210102 Phase 1 Study (NCT05269381) - Initiation & Completion Year
Figure 7-5: INTerpath-002 Phase 3 Study (NCT06077760) - Initiation & Completion Year
Figure 7-6: INTerpath-009 Phase 3 Study (NCT06623422) - Initiation & Completion Year
Figure 7-7: KEYNOTE-603 Phase 1 Study (NCT03313778) - Initiation & Completion Year
Figure 7-8: MCC-20915 Phase 2 Study (NCT05325632) - Initiation & Completion Year
Figure 7-9: FK-PC101-01 Phase 2 Study (NCT06636682) - Initiation & Completion Year
Figure 7-10: 19-039 Phase 1 Study (NCT04161755) - Initiation & Completion Year
Figure 7-11: IMCODE003 Phase 2 Study (NCT05968326) - Initiation & Completion Year
Figure 7-12: GT-30 Phase 1/2 Study (NCT04251117) - Initiation & Completion Year
Figure 7-13: QUILT 502 Phase 1/2 Study (NCT06253494) - Initiation & Completion Year
Figure 9-1: BioNTech - iNeST
Figure 9-2: BioVaxys - DPX & Haptenix Platforms
Figure 9-3: CureVac - proprietary mRNA technology
Figure 9-4: Evaxion -Proprietary Technologies
Figure 9-5: Geneos - GT-EPIC Platform
Figure 9-6: Moderna - mRNA Design Studio Features
Figure 9-7: myNEO Therapeutics - ImmunoEngine
Figure 9-8: Nouscom - Unnamed Technology
Figure 9-9: Nykode Therapeutics - Vaccibody Structure
Figure 9-10: Nykode Therapeutics - Vaccibody Mechanism Of Action
Figure 9-11: Transgene - myvac Platform
Figure 10-1: Global Personalized Cancer Vaccines Market - Drivers & Opportunities
Figure 10-2: Global Personalized Cancer Vaccines Market - Challenges & Restraints

List of Tables

Table 5-1: Personalized Cancer Vaccines By Developer, Indication & Phase
Table 7-1: Melanoma - Personalized Vaccines In Clinical Trials
Table 7-2: Lung Cancer - Personalized Vaccines In Clinical Trials
Table 7-3: Breast Cancer - Personalized Vaccines In Clinical Trials
Table 7-4: Prostate Cancer - Personalized Vaccines In Clinical Trials
Table 7-5: Gastrointestinal Cancer - Personalized Vaccines In Clinical Trials
Table 7-6: Gynecological Cancer - Personalized Vaccines In Clinical Trials
Table 7-7: Brain Cancer - Personalized Vaccines In Clinical Trials
Table 7-8: Hematological Malignancies - Personalized Vaccines In Clinical Trials

02-2729-4219

+886-2-2729-4219